Novel Nanolipoidal Systems for the Management of Skin Cancer

Apoorva       Singh; Nimisha
Abstract

Skin cancer, among the various kinds of cancers, is a type that emerges from skin due to the growth of abnormal cells. These cells are capable of spreading and invading the other parts of the body. The occurrence of non-melanoma and melanoma, which are the major types of skin cancers, has increased over the past decades. Exposure to ultraviolet radiations (UV) is the main associative cause of skin cancer. UV exposure can inactivate tumor suppressor genes while activating various oncogenes. The conventional techniques like surgical removal, chemotherapy and radiation therapy lack the potential for targeting cancer cells and harm the normal cells. However, the novel therapeutics show promising improvements in the effectiveness of treatment, survival rates and better quality of life for patients. Different methodologies are involved in the skin cancer therapeutics for delivering the active ingredients to the target sites. Nano carriers are very efficient as they have the ability to improve the stability of drugs and further enhance their penetration into the tumor cells. The recent developments and research in nanotechnology have entitled several targeting and therapeutic agents to be incorporated into nanoparticles for an enhancive treatment of skin cancer. To protect the research works in the field of nanolipoidal systems various patents have been introduced. Some of the patents acknowledge responsive liposomes for specific targeting, nanocarriers for the delivery or co-delivery of chemotherapeutics, nucleic acids as well as photosensitizers. Further recent patents on the novel delivery systems have also been included here.
Keywords: Melanoma, non-melanoma, novel therapeutics, recent patents, skin cancer, ultraviolet radiations.
Graphical Abstract

[1] 
Taveira SF, Lopez RV. Topical administration of anticancer drugs for skin cancer treatment Topical Administration of anticancer drugs for skin cancer treatment  2011; 247-72.
[2] 
WHO. Cancer-fact sheets http://www.who.int/mediacentre/factsheets/fs297/en/index.html
[3] 
Haque T, Rahman KM, Thurston DE, Hadgraft J, Lane ME. Topical therapies for skin cancer and actinic keratosis. Eur J Pharm Sci  2015; 77: 279-89.
[http://dx.doi.org/10.1016/j.ejps.2015.06.013] [PMID: 26091570] 
[4] 
Akhter MH, Rizwanullah M, Ahmad J, Ahsan MJ, Mujtaba MA, Amin S. Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics. Artif Cells Nanomed Biotechnol  2018; 46(5): 873-84.
[http://dx.doi.org/10.1080/21691401.2017.1366333] [PMID: 28830262] 
[5] 
Naves LB, Dhand C, Venugopal JR, Rajamani L, Ramakrishna S, Almeida L. Nanotechnology for the treatment of melanoma skin cancer. Prog Biomater  2017; 6(1-2): 13-26.
[http://dx.doi.org/10.1007/s40204-017-0064-z] [PMID: 28303522] 
[6] 
Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther (Heidelb)  2017; 7(1)(Suppl. 1): 5-19.
[http://dx.doi.org/10.1007/s13555-016-0165-y] [PMID: 28150105] 
[7] 
Kim Y, He YY. Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammation. Genes Dis  2014; 1(2): 188-98.
[http://dx.doi.org/10.1016/j.gendis.2014.08.005] [PMID: 25642450] 
[8] 
Donglikar MM, Deore SL. Sunscreens. RE:view  2016; 8(3)
[http://dx.doi.org/10.5530/pj.2016.3.1] 
[9] 
McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch Dermatol  1997; 133(5): 593-6.
[http://dx.doi.org/10.1001/archderm.1997.03890410049006] [PMID: 9158412] 
[10] 
Goldenberg G, Golitz LE, Fitzpatrick J. Histopathology of skin cancer InManaging Skin Cancer.  Berlin, Heidelberg: Springer 2010; pp. 17-35.
[11] 
Orthaber K, Pristovnik M, Skok K, Perić B, Maver U. Skin cancer and its treatment: novel treatment approaches with emphasis on nanotechnology. J Nanomater  2017; 1-20.
[http://dx.doi.org/10.1155/2017/2606271] 
[12] 
Schadendorf D, van Akkooi ACJ, Berking C. Melanoma. Lancet  2018; 392(10151): 971-84.
[http://dx.doi.org/10.1016/S0140-6736(18)31559-9] [PMID: 30238891] 
[13] 
Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol  2009; 27(36): 6199-206.
[http://dx.doi.org/10.1200/JCO.2009.23.4799] [PMID: 19917835] 
[14] 
https://www.everydayhealth.com/skin-cancer/types/
[15] 
Lawton S. Skin 1: the structure and functions of the skin. Nurs Times  2019; 115(12): 30-3.
[16] 
Wertz PW, Downing DT. Stratum corneum: biological and biochemical considerations Transdermal drug delivery  1989; 1-22.
[17] 
Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res  2003; 42(1): 1-36.
[http://dx.doi.org/10.1016/S0163-7827(02)00028-0] [PMID: 12467638] 
[18] 
Benson HA. Skin structure, function, and permeation.  Transdermal and Topical Drug Delivery 2012; p. 1.
[19] 
Plotczyk M, Higgins CA. Skin biology Biomaterials for Skin Repair and Regeneration  2019; 3-25.
[http://dx.doi.org/10.1016/B978-0-08-102546-8.00001-7] 
[20] 
McGrath JA, Eady RA, Pope FM. Anatomy and organization of human skin Rook’s textbook of dermatology 2004.
[http://dx.doi.org/10.1002/9780470750520.ch3] 
[21] 
Ito S, Wakamatsu K. Quantitative analysis of eumelanin and pheomelanin in humans, mice, and other animals: a comparative review. Pigment Cell Res  2003; 16(5): 523-31.
[http://dx.doi.org/10.1034/j.1600-0749.2003.00072.x] [PMID: 12950732] 
[22] 
Park HY, Kosmadaki M, Yaar M, Gilchrest BA. Cellular mechanisms regulating human melanogenesis. Cell Mol Life Sci  2009; 66(9): 1493-506.
[http://dx.doi.org/10.1007/s00018-009-8703-8] [PMID: 19153661] 
[23] 
Elias PM. Structure and function of the stratum corneum permeability barrier. Drug Dev Res  1988; 13(2‐3): 97-105.
[http://dx.doi.org/10.1002/ddr.430130203] 
[24] 
Guimarães KL, Ré MI. Lipid nanoparticles as carriers for cosmetic ingredients: The first (SLN) and the second generation (NLC) InNanocosmetics and nanomedicines.  Berlin, Heidelberg: Springer 2011; pp. 101-22.
[25] 
Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm  2007; 345(1-2): 163-71.
[http://dx.doi.org/10.1016/j.ijpharm.2007.05.061] [PMID: 17644288] 
[26] 
Herai H, Gratieri T, Thomazine JA, Bentley MV, Lopez RF. Doxorubicin skin penetration from monoolein-containing propylene glycol formulations. Int J Pharm  2007; 329(1-2): 88-93.
[http://dx.doi.org/10.1016/j.ijpharm.2006.08.021] [PMID: 17027205] 
[27] 
Manconi M, Sinico C, Caddeo C, Vila AO, Valenti D, Fadda AM. Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin. Int J Pharm  2011; 412(1-2): 37-46.
[http://dx.doi.org/10.1016/j.ijpharm.2011.03.068] [PMID: 21530626] 
[28] 
Simonetti LD, Gelfuso GM, Barbosa JC, Lopez RF. Assessment of the percutaneous penetration of cisplatin: the effect of monoolein and the drug skin penetration pathway. Eur J Pharm Biopharm  2009; 73(1): 90-4.
[http://dx.doi.org/10.1016/j.ejpb.2009.04.016] [PMID: 19442727] 
[29] 
Singh BN, Singh RB, Singh J. Effects of ionization and penetration enhancers on the transdermal delivery of 5-fluorouracil through excised human stratum corneum. Int J Pharm  2005; 298(1): 98-107.
[http://dx.doi.org/10.1016/j.ijpharm.2005.04.004] [PMID: 15913928] 
[30] 
Steluti R, De Rosa FS, Collett J, Tedesco AC, Bentley MV. Topical glycerol monooleate/propylene glycol formulations enhance 5-aminolevulinic acid in vitro skin delivery and in vivo protophorphyrin IX accumulation in hairless mouse skin. Eur J Pharm Biopharm  2005; 60(3): 439-44.
[http://dx.doi.org/10.1016/j.ejpb.2005.01.011] [PMID: 15996585] 
[31] 
Pierre MB, Ricci E Jr, Tedesco AC, Bentley MV. Oleic acid as optimizer of the skin delivery of 5-aminolevulinic acid in photodynamic therapy. Pharm Res  2006; 23(2): 360-6.
[http://dx.doi.org/10.1007/s11095-005-9261-x] [PMID: 16341572] 
[32] 
Bugaj A, Juzeniene A, Juzenas P, Iani V, Ma LW, Moan J. The effect of skin permeation enhancers on the formation of porphyrins in mouse skin during topical application of the methyl ester of 5-aminolevulinic acid. J Photochem Photobiol B  2006; 83(2): 94-7.
[http://dx.doi.org/10.1016/j.jphotobiol.2005.12.003] [PMID: 16442808] 
[33] 
Campos PM, Bentley MV, Torchilin VP. Nanopreparations for skin cancer therapy Nanobiomaterials in Cancer Therapy  2016; 1-28.
[http://dx.doi.org/10.1016/B978-0-323-42863-7.00001-3] 
[34] 
Gratieri T, Gelfuso GM, Lopez RF. Basic principles and applications of iontophoresis for cutaneous penetration of drugs. Quim Nova  2008; 31(6): 1490-8.
[http://dx.doi.org/10.1590/S0100-40422008000600040] 
[35] 
Tesselaar E, Sjöberg F. Transdermal iontophoresis as an in-vivo technique for studying microvascular physiology. Microvasc Res  2011; 81(1): 88-96.
[http://dx.doi.org/10.1016/j.mvr.2010.11.002] [PMID: 21070791] 
[36] 
Weaver JC, Chizmadzhev Y. Electroporation Biological and Medical Aspects of Electromagnetic Fields. Fourth Edition  2018; 243-84.
[37] 
Prausnitz MR, Lee CS, Liu CH. Transdermal transport efficiency during skin electroporation and iontophoresis. J Control Release  1996; 38(2-3): 205-17.
[http://dx.doi.org/10.1016/0168-3659(95)00121-2] 
[38] 
Dianzani C, Zara GP, Maina G. Drug delivery nanoparticles in skin cancers. BioMed Res Int 2014.2014895986
[http://dx.doi.org/10.1155/2014/895986] [PMID: 25101298] 
[39] 
Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol  2016; 44(1): 381-91.
[http://dx.doi.org/10.3109/21691401.2014.953633] [PMID: 25222036] 
[40] 
Schmid MH, Korting HC. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Deliv Rev  1996; 18(3): 335-42.
[http://dx.doi.org/10.1016/0169-409X(95)00019-4] 
[41] 
Santana MH, Zanchetta B. Elastic liposomes InNanocosmetics and Nanomedicines.  Berlin, Heidelberg: Springer 2011; pp. 139-62.
[http://dx.doi.org/10.1007/978-3-642-19792-5_7] 
[42] 
Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci  2001; 6(1): 66-77.
[http://dx.doi.org/10.1016/S1359-0294(00)00090-X] 
[43] 
Lamichhane N, Udayakumar TS, D’Souza WD. Liposomes: clinical applications and potential for image-guided drug delivery. Molecules  2018; 23(2): 288.
[http://dx.doi.org/10.3390/molecules23020288] [PMID: 29385755] 
[44] 
Gilani SJ, Jahangir MA. Chandrakala. Nano-based therapy for treatment of skin cancer. Recent Pat Antiinfect Drug Discov  2018; 13(2): 151-63.
[http://dx.doi.org/10.2174/1574891X13666180911095440] [PMID: 30205801] 
[45] 
Das SK, Chakraborty S, Roy C. Ethosomes as novel vesicular carrier: An overview of the principle, preparation and its applications. Curr Drug Deliv  2018; 15(6): 795-817.
[http://dx.doi.org/10.2174/1567201815666180116091604] [PMID: 29336262] 
[46] 
Garg V, Singh H, Bimbrawh S. Ethosomes and transfersomes: principles, perspectives and practices. Curr Drug Deliv  2017; 14(5): 613-33.
[http://dx.doi.org/10.2174/1567201813666160520114436] [PMID: 27199229] 
[47] 
Ag Seleci D, Seleci M, Walter JG, Stahl F, Scheper T. Niosomes as nanoparticular drug carriers: fundamentals and recent applications. Journal of nanomaterials 2016.
[http://dx.doi.org/10.1155/2016/7372306] 
[48] 
Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. Anticancer Drugs  2011; 22(8): 774-82.
[http://dx.doi.org/10.1097/CAD.0b013e328346c7d6] [PMID: 21799471] 
[49] 
Parnham MJ, Wetzig H. Toxicity screening of liposomes. Chem Phys Lipids  1993; 64(1-3): 263-74.
[http://dx.doi.org/10.1016/0009-3084(93)90070-J] [PMID: 8242838] 
[50] 
Rahman A, Uahengo V, Likius D. Mini review on emerging methods of preparation of liposome and its application as Liposome drug delivery systems Open J Pharmacol Pharmacother  2018; 3(1): 05-21.
[51] 
Devi M, Kumar MS, Mahadevan N. Amphotericin-B loaded vesicular systems for the treatment of topical fungal infection. Int J Rec Adv Pharm Res  2011; 4: 37-46.
[52] 
Ghanbarzadeh S, Valizadeh H, Zakeri-Milani P. Application of response surface methodology in development of sirolimus liposomes prepared by thin film hydration technique. Bioimpacts  2013; 3(2): 75-81.
[PMID: 23878790] 
[53] 
Akbarzadeh A, Rezaei-Sadabady R, Davaran S. Liposome: classification, preparation, and applications. Nanoscale Res Lett  2013; 8(1): 102.
[http://dx.doi.org/10.1186/1556-276X-8-102] [PMID: 23432972] 
[54] 
Olga Popovska JS, Kavrakovski Z, Rafajlovska V. An Overview: Methods for Preparation and Characterization of Liposomes as Drug Delivery Systems Int. J Pharm Phytopharmacol  2013; 3(2): 13-20.
[55] 
Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett  2005; 10(4): 711-9.
[PMID: 16341279] 
[56] 
Ramana LN, Sethuraman S, Ranga U, Krishnan UM. Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci  2010; 17(1): 57.
[http://dx.doi.org/10.1186/1423-0127-17-57] [PMID: 20624325] 
[57] 
Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine  2011; 6: 1155-66.
[PMID:  21822379] 
[58] 
Liu L, Yonetani T. Preparation and characterization of liposome-encapsulated haemoglobin by a freeze-thaw method. J Microencapsul  1994; 11(4): 409-21.
[http://dx.doi.org/10.3109/02652049409034258] [PMID: 7931940] 
[59] 
Jose A, Labala S, Ninave KM, Gade SK, Venuganti VVK. Effective skin cancer treatment by topical co-delivery of curcumin and STAT3 siRNA using cationic liposomes. AAPS PharmSciTech  2018; 19(1): 166-75.
[http://dx.doi.org/10.1208/s12249-017-0833-y] [PMID: 28639178] 
[60] 
Petrilli R, Eloy JO, Saggioro FP, et al. Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. J Control Release  2018; 283: 151-62.
[http://dx.doi.org/10.1016/j.jconrel.2018.05.038] [PMID: 29864476] 
[61] 
Abu Lila AS, Doi Y, Nakamura K, Ishida T, Kiwada H. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J Control Release  2010; 142(2): 167-73.
[http://dx.doi.org/10.1016/j.jconrel.2009.10.020] [PMID: 19861140] 
[62] 
Watanabe M, Kawano K, Toma K, Hattori Y, Maitani Y. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J Control Release  2008; 127(3): 231-8.
[http://dx.doi.org/10.1016/j.jconrel.2008.02.005] [PMID: 18384903] 
[63] 
Pierre MB, Tedesco AC, Marchetti JM, Bentley MV. Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: preparation and in vitro permeation study. BMC Dermatol  2001; 1(1): 5.
[http://dx.doi.org/10.1186/1471-5945-1-5] [PMID: 11545679] 
[64] 
Rai S, Pandey V, Rai G. Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: the state of the art Nano reviews   experiments  2017; 8-1.
[http://dx.doi.org/10.1080/20022727.2017.1325708] 
[65] 
Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta  1992; 1104(1): 226-32.
[http://dx.doi.org/10.1016/0005-2736(92)90154-E] [PMID: 1550849] 
[66] 
Chaurasiya P, Ganju E, Upmanyu N, Ray SK, Jain P. Transfersomes: a novel technique for transdermal drug delivery. J Drug Deliv Ther  2019; 9(1): 279-85.
[http://dx.doi.org/10.22270/jddt.v9i1.2198] 
[67] 
Bhasin B, Londhe VY. An overview of transfersomal drug delivery. Int J Pharm Sci Res  2018; 9(6): 2175-84.
[68] 
Singh HP, Utreja P, Tiwary AK, Jain S. Elastic liposomal formulation for sustained delivery of colchicine: in vitro characterization and in vivo evaluation of anti-gout activity. AAPS J  2009; 11(1): 54-64.
[http://dx.doi.org/10.1208/s12248-008-9078-8] [PMID: 19191031] 
[69] 
Szoka F Jr, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA  1978; 75(9): 4194-8.
[http://dx.doi.org/10.1073/pnas.75.9.4194] [PMID: 279908] 
[70] 
Rai K, Gupta Y, Jain A, Jain SK. Transfersomes: self-optimizing carriers for bioactives. PDA J Pharm Sci Technol  2008; 62(5): 362-79.
[PMID:  19055232] 
[71] 
Fadel M, Samy N, Nasr M, Alyoussef AA. Topical colloidal indocyanine green-mediated photodynamic therapy for treatment of basal cell carcinoma. Pharm Dev Technol  2017; 22(4): 545-50.
[http://dx.doi.org/10.3109/10837450.2016.1146294] [PMID: 26895257] 
[72] 
Jain S, Jain N. PUB040 Formulation and evaluation of embelin loaded transfersome for effective treatment of skin cancer. J Thorac Oncol  2017; 12(11): S2378.
[http://dx.doi.org/10.1016/j.jtho.2017.09.1903] 
[73] 
Khan MA, Pandit J, Sultana Y. Novel carbopol-based transfersomal gel of 5-fluorouracil for skin cancer treatment: in vitro characterization and in vivo study. Drug Deliv  2015; 22(6): 795-802.
[http://dx.doi.org/10.3109/10717544.2014.902146] [PMID: 24735246] 
[74] 
Gupta V, Karthikeyan C, Trivedi P. Localized delivery of cisplatin for the effective management of squamous cell carcinoma from protransfersome formulation. Arch Pharm Res  2012; 35(5): 851-9.
[http://dx.doi.org/10.1007/s12272-012-0510-3] [PMID: 22644852] 
[75] 
Fadel M, Abdelbary G, Elmenshawe SF, Eissa E. Toluidine blue loaded transferosomes for topical photodynamic therapy: for-mulation and characterization International journal of research in pharmaceutical sciences  2011; 2(4): 537-44.
[76] 
Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes-a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm  2003; 29(9): 1013-26.
[http://dx.doi.org/10.1081/DDC-120025458] [PMID: 14606665] 
[77] 
Mahmood S, Taher M, Mandal UK. Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. Int J Nanomedicine  2014; 9: 4331-46.
[PMID:  25246789] 
[78] 
Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses Cochrane Database of systematic reviews 2012; (12): 
[http://dx.doi.org/10.1002/14651858.CD004415.pub2 ] 
[79] 
Cosco D, Paolino D, Maiuolo J, et al. Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery. Int J Pharm  2015; 489(1-2): 1-10.
[http://dx.doi.org/10.1016/j.ijpharm.2015.04.056] [PMID: 25899287] 
[80] 
Lin MW, Huang YB, Chen CL, et al. A formulation study of 5-aminolevulinic encapsulated in DPPC liposomes in melanoma treatment. Int J Med Sci  2016; 13(7): 483-9.
[http://dx.doi.org/10.7150/ijms.15411] [PMID: 27429584] 
[81] 
Dorrani M, Garbuzenko OB, Minko T, Michniak-Kohn B. Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy. J Control Release  2016; 228: 150-8.
[http://dx.doi.org/10.1016/j.jconrel.2016.03.010] [PMID: 26965957] 
[82] 
https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download
[83] 
Fatima Z. Formulation and performance evaluation of Berberis aristata extract loaded ethosomal gel Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm 2017; 11(03)
[84] 
Nimisha, Rizvi DA, Fatima Z, Neema, Kaur CD. Nimisha, Rizvi DA, Fatima Z, Neema, Kaur CD. Antipsoriatic and anti inflammatory studies of Berberis aristata extract loaded nanovesicular gels. Pharmacogn Mag  2017; 13(Suppl. 3): S587-94.
[http://dx.doi.org/10.4103/pm.pm_210_17] [PMID: 29142419] 
[85] 
Nimisha Singh A. Enhancement of Dissolution Rate of Quercetin using Solid Dispersion Approach: In vitro In vivo Evaluation. Nanoscience Nanotechnology Asia  2019; 1.
[86] 
Nimisha FZ. Kaur CD. A review on potential of novel vesicular carriers for carrying herbal drugs in the treatment of dermatological disorders. Journal of Atoms and Molecules  2016; 6(3): 987.
[http://dx.doi.org/10.1016/j.ajps.2018.05.007] 
[87] 
Seiberg M, Shapiro SS, Paine C, Conney AH, Huang MT. Topical anti-cancer compositions and methods of use thereof United States patent US 7,309,688 2007.
[88] 
Jin Z, Muramatsu K, Yamada H, Fuwa N, Hibasami H. Skin cancer preventive agent United States patent application US 09/863,316, 2001.
[89] 
Sampalis T. Neptune Technologies Bioressources Inc, assignee. Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport US patent application 10/481,040 2004.
[90] 
HuaqingL. Tacrolimus transfersome solution and preparation method thereof Guangdong Pharmaceutical College, China CN 102949341B 2014.
[91] 
Battaglia G. Epithelial delivery United States patent US 10,525,004, 2020.
[92] 
Kam K, Wang Z, Morton S, Peck N. ROS—responsive liposomes for specific targeting United States patent US 10,517,823, 2019.
[93] 
Lin W, He C, Liu D. Nanoscale carriers for the delivery or codelivery of chemotherapeutics, nucleic acids and photosensitizers United States patent US 10,517,822, 2019.
[94] 
Devane JG, Stark P, Fanning N, Rekhi GS, Jenkins SA, Liversidge G. Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone United States patent application US 11/768,169, 2008.
[95] 
Daftarian PM, Mansour M, Pohajdak B, Brown RG, Kast WM. Use of Liposomes in a Carrier Comprising a Continuous Hydrophobic Phase as a Vehicle for Cancer Treatment United States patent application US 12/083,209, 2009.
[96] 
Person JR. Skin cancer prevention method and product United States patent application US 11/196,946, 2010.
[97] 
Turos E, Greenhalgh KR, Garay JC.  Nanoparticles with covalently bound surfactant for drug delivery United States patent US 8,414,926, 2013.
[98] 
Jain RK, Boucher Y, Chauhan VP. General Hospital Corp, XTUIT PHARMACEUTICALS Inc, assignee. Novel compositions and uses of anti-hypertension agents for cancer therapy. United States patent application US 13/834,094, 2013.
[99] 
Birbara PJ. API Genesis LLC, assignee.  Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds United States patent US 8,637,569 2014.
[100] 
Poznansky MC, Potts JT Jr, Vianello F, Papeta N. General Hospital Corp, assignee. Antifugetactic agents for the treatment of skin cancers United States patent application US 14/936,604 2016.
[101] 
Kulkarni PS, Haldar MK, Mallik S, Srivastava DK. North Dakota State University Research Foundation, assignee. Controlled release nanoparticles and methods of use United States patent US 9,457,041 2016.
[102] 
Markovic SN, Nevala WK. Mayo Foundation for Medical Education, assignee. Nanoparticle complexes of anti-CD20 antibodies, albumin and paclitaxel United States patent US 9,757,453 2017.
[103] 
Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol  2015; 141(5): 769-84.
[http://dx.doi.org/10.1007/s00432-014-1767-3] [PMID: 25005786] 
[104] 
Kolenyak dos Santos F, Helena Oyafuso M, Priscila Kiill C, Palmira Daflon-Gremiao M, Chorilli M. Nanotechnology-based drug delivery systems for treatment of hyperproliferative skin diseases-a review. Curr Nanosci  2013; 9(1): 159-67.
[105] 
Sharma P, Mehra NK, Jain K, Jain NK. Biomedical applications of carbon nanotubes: a critical review. Curr Drug Deliv  2016; 13(6): 796-817.
[http://dx.doi.org/10.2174/1567201813666160623091814] [PMID: 27339036] 
[106] 
Vannucci L, Falvo E, Fornara M. Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles. Int J Nanomedicine  2012; 7: 1489-509.
[PMID:  22619508] 
[107] 
Ma M, Hao Y, Liu N. A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution. Int J Nanomedicine  2012; 7: 3389-98.
[http://dx.doi.org/10.2147/IJN.S29827] [PMID: 22848167] 
[108] 
Chomoucka J, Drbohlavova J, Huska D, Adam V, Kizek R, Hubalek J. Magnetic nanoparticles and targeted drug delivering. Pharmacol Res  2010; 62(2): 144-9.
[http://dx.doi.org/10.1016/j.phrs.2010.01.014] [PMID: 20149874] 
[109] 
Xiong H, Diao Q, Jin R, Song D, Wang X, Sun Y. Synthesis and application of thiol-functionalized magnetic nanoparticles for studying interactions of epirubicin hydrochloride with bovine serum albumin by fluorescence spectrometry. Luminescence  2017; 32(2): 142-8.
[http://dx.doi.org/10.1002/bio.3158] [PMID: 27193868] 
[110] 
Alexander A, Dwivedi S. Ajazuddin. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release  2012; 164(1): 26-40.
[http://dx.doi.org/10.1016/j.jconrel.2012.09.017] [PMID: 23064010] 
[111] 
Safari J, Zarnegar Z. Advanced drug delivery systems: Nanotechnology of health design A review. J Saudi Chem Soc  2014; 18(2): 85-99.
[http://dx.doi.org/10.1016/j.jscs.2012.12.009] 
[112] 
Pandey K. Nimisha. An Overview on Promising Nanotechnological Approaches for the Treatment of Psoriasis. Recent Pat Nanotechnol  2020; 14: 1.
[http://dx.doi.org/10.2174/1872210514666200204124130] [PMID: 32013854] 
Cite As
Recent Patents on Drug Delivery & Formulation

Novel Nanolipoidal Systems for the Management of Skin Cancer

Abstract

Graphical Abstract
